Dr Reddy's Q2 Review: Brokerages Flag Margin Recovery As Key Growth Driver — Check Target Price, Potential Upside
NDTV Profit
Dr. Reddy's Laboratories delivered a sharp margin recovery and beat profit expectations despite largely in-line revenue. Brokerages highlighted operating efficiencies and a stronger product mix, while identifying semaglutide supplies and abatacept approval…
Summary from NDTV Profit
Read the full story on NDTV Profit
